Successful treatment of a 3‐year‐old girl with generalized pustular psoriasis using secukinumab monotherapy
Huiying Zhu, Pingping Song, Donghong Du, Hongqing Tian
Abstract
We report a case of a 3-year-old girl with generalized pustular psoriasis (GPP) and a compound heterozygous mutation within the IL36 receptor antagonist (IL36RN) gene at c.28C>T and c.115+6T>C, who was successfully treated using secukinumab monotherapy. The first dose of secukinumab (150 mg) was administered subcutaneously, followed by 75 mg of secukinumab subcutaneously once weekly for 4 weeks and then 75 mg every 4 weeks. The total course of treatment was 4 months, with a total of 8 doses. A PASI score of 75 and 100 was achieved at weeks 1 and 2, respectively, and maintained for 11 months of follow-up, without disease recurrence or adverse events.
Topics & Concepts
SecukinumabMedicineGeneralized pustular psoriasisDermatologyPsoriasisAdverse effectGirlPlaque psoriasisInternal medicinePsoriatic arthritisDevelopmental psychologyPsychologyPsoriasis: Treatment and PathogenesisDermatology and Skin DiseasesAsthma and respiratory diseases